TipRanks on MSN

Atossa completes FDA meeting on regulatory strategies

Atossa Therapeutics ( ($ATOS) ) has shared an announcement. On December 4, 2025, Atossa Therapeutics announced the completion of a Type C meeting ...

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Research and development expenses were $27.1 million for the third quarter of 2025, compared to $16.8 million for the third quarter of 2024. The increase primarily reflects increases in clinical trial ...
Contract Pharma

Quotient Sciences, Intrepid Labs Partner to Advance AI in Early Drug Development

Quotient Sciences and Intrepid Labs have announced a multi-year strategic partnership to advance the use of artificial ...

[Latest] Global 4D Printing in Healthcare Market Size/Share Worth USD 14240 Million by 2034 at a 84.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Repo…

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's ...